menu
    • menu
    [{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TRx-237-801","moa":"Tau protein","graph1":"Neurology","graph2":"IND Enabling","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TauRx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Hydromethylthionine Mesylate","moa":"Tau protein aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TauRx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SINGAPORE","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Hydromethylthionine Mesylate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"TauRx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"TauRx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"TauRx Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by TauRx Therapeutics

    Menu

    TauRx Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TauRx Submits UK Marketing Application for HMTM as Alzheimer’s Disease Treatment

                            Details : TRx0237 (hydromethylthionine mesylate), is an investigational small molecule Tau protein inhibitor, for the treatment of mild to moderate Alzheimer’s disease. The company has submitted MAA in UK.

                            Brand Name : TRx0237

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 01, 2024

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TauRx's LUCIDITY Trial Indicates Two-Year Sustained Cognitive Benefits of HMTM

                            Details : TauRx's lead product candidate TRx0237 (hydromethylthionine), a tau protein inhibitor. Currently, it is being evaluated in the Phase 3 clinical trial studies for the treatment of Alzheimer's disease.

                            Brand Name : TRx0237

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 07, 2024

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LUCIDITY Phase 3 Topline Data Presented At CTAD For HMTM - The Only Oral Anti-Tau Therapy In Late-stage Develo...

                            Details : TRx0237 is a small molecule drug being tested for its ability to inhibit aggregation of tau, a protein that forms neurofibrillary tangles in the brains of people with Alzheimer's and other neurodegenerative diseases.

                            Brand Name : TRx0237

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 30, 2022

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            TauRx Announces Additional Investment of USD119 Million Following Announcement Of Phase 3 LUCIDITY Topline Res...

                            Details : HMTM or TRx0237 is an oral tau aggregation inhibitor, targeting this underlying pathology. TauRx’s HMTM has the potential to become the first disease-modifying therapies (DMT) targeting tau to be approved for AD.

                            Brand Name : TRx0237

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 14, 2022

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regulatory Submi...

                            Details : For people with early Alzheimer’s (MCI), HMTM, a potent inhibitor of Tau aggregation treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals.

                            Brand Name : TRx0237

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 06, 2022

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tau-Targeting Alzheimer's Treatment, HMTM, Moving Toward Regulatory Submission Based on Initial Data From TauR...

                            Details : TauRx's lead investigative oral drug, TRx0237, has been tested in 598 people with Alzheimer's. Following our 12 month blinded phase of the study, participants have moved forward to an additional one year open label phase.

                            Brand Name : TRx0237

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 01, 2022

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TauRx's Late-Stage Clinical Trial Reaches New Milestone

                            Details : This milestone means TauRx will now progress to the data cleaning and analysis phase which enables the company to determine topline results on the safety and efficacy of Hydromethylthionine mesylate (HMTM).

                            Brand Name : TRx0237

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 14, 2022

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRx-237-801

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Trial Approval in China Supports Global Development Strategy for TauRx’s Oral Tau Aggregation Inhibitor

                            Details : IND approval was formally given on 10 March 2022 paving the way for TauRx to build on its global strategy to bring to market the first disease modifying treatment for Alzheimer’s disease targeting the tau pathology of Alzheimer’s disease (AD).

                            Brand Name : TRx-237-801

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 13, 2022

                            Lead Product(s) : TRx-237-801

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed

                            TauRx Therapeutics

                            Singapore arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TauRx Reveals Study Results That Offer New Hope for Treatment of Patients With Dementia

                            Details : Minimum dose of hydromethylthionine could slow clinical decline and brain atrophy in behavioural variant Fronto-Temporal Dementia as well as Alzheimer's Disease.

                            Brand Name : TRx0237

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 19, 2020

                            Lead Product(s) : Hydromethylthionine Mesylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth